Heart Metabolics Report issue

For profit Phase 3
Founded: San Francisco CA United States (2012)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2016
NCT02431221
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Heart Metabolics Limited

Active Ingredients

Drugs in Phase 3 Trials (1)

perhexiline (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 3)

Cardiomyopathy, Hypertrophic (Phase 3)

Cardiomyopathy, Hypertrophic, Familial (Phase 2)

Heart Failure (Phase 3)

Hypertrophy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1